AVIR – atea pharmaceuticals, inc. - common stock (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

AVIR

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/5

06:58 pm

avir

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript [Seeking Alpha]

High Report

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript [Seeking Alpha]

Report

3/5

06:54 pm

avir

Atea Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]

High Report

Atea Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]

Report

3/5

04:31 pm

avir

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]

High Report

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]

Report

3/5

04:05 pm

avir

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

High Report

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Report

2/26

07:32 am

avir

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 [Yahoo! Finance]

Low Report

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 [Yahoo! Finance]

Report

2/26

07:00 am

avir

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Low Report

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Report

2/24

07:00 am

avir

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Low Report

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.